With $11.2M in new funding led by Two Bear Capital, Talus Bio is set to revolutionize the way we approach drug discovery. Our MARMOT platform is using proteomics and AI to lead the charge against previously "undruggable" transcription factors. Thanks to Gabrielle Masson for highlighting our work https://lnkd.in/gDnp48pW
Talus Bio
Biotechnology Research
Seattle, WA 3,135 followers
Gene regulator profiling in live cells for drug development
About us
Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics. As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery: - Developing internal programs against previously undruggable gene regulators in cancers with poor standard of care - Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs
- Website
-
http://talus.bio
External link for Talus Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Seattle, WA
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
550 17th Ave
Suite 550
Seattle, WA 98122, US
Employees at Talus Bio
-
Michelle Briscoe
Chief Operating Officer and Chief Financial Officer at Talus Bio | Co-founder & Board Member of OUTbio - Seattle 🏳️🌈 | Board Member of HBA -…
-
Stephen (Steve) Letrent
Chief Development Officer
-
Alex Federation
Co-Founder and CEO at Talus Bio - nothing is "undruggable" - therapeutics historically intractable transcription factors in cancer and beyond
-
Omri Amirav-Drory
General Partner at NFX
Updates
-
Don’t miss this opportunity to hear a great proteomics discussion including one of the world’s leading experts, Talus Bio CTO Lindsay Pino!
New GEN Live! Is Proteomics the Next Big "Ome"? Wednesday, July 17, 2024 9:00 am PT, 12:00 pm ET, 18:00 CET On this episode of GEN Live, we will talk about proteomics—as a tool and as a field. Where is it now and what type of research is proteomics enabling? REGISTER: https://ow.ly/tFHi50Su5B9 #Omics Benjamin Neely Lindsay Pino
-
Thanks to World Industry News for including Talus Bio on your list of notable proteomics companies!
Proteomics Market Worth $72.9 Billion by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dhpT8i-f The global proteomics market in terms of revenue was estimated to be worth $36.8 billion in 2023 and is poised to reach $72.9 billion by 2028, growing at a CAGR of 14.6% from 2023 to 2028. Companies From the Market Navinci Diagnostics eBioscience Medical Supply Company (MSC) BGI Genomics Xcellogen Biotech India Pvt Ltd Instituto de Agroquímica y Tecnología de Alimentos IATA CSIC IonOpticks Eurogentec Kura Biotech Source BioScience RCSB Protein Data Bank Rigaku Cambridge Innovation Capital PT Sciencewerke Takara Bio Europe Talus Bio The Science Advisory Board BigOmics Analytics Pixelgen Technologies Hologic Diagenode Medicinski fakultet Sveučilišta u Zagrebu Institute of Molecular and Cell Biology (IMCB) Spanish National Bioinformatics Institute (INB) Uniscience do Brasil Macrogen Inc. Covant Therapeutics International Max Planck Research School on Cellular Biophysics (IMPRS-CBP) Tarsons Products Limited MAOLAC Decoding Nature RXCELERATE LIMITED Cultek BioAnalysis, LLC Philippine Genome Center Inoviv Protavio Ltd SYNCELL INC. Magnet Biomedicine Vienna BioCenter Core Facilities (VBCF) GmbH
-
All 16 employees of Talus Bio enjoyed a little artistic stimulation at Tapster SLU last week! With a lot of help from our wonderful instructor from Stir Up the Paint, we created custom tote bags reflecting some of the beauty of the Pacific Northwest mountains and forests while sampling some tasty libations. A win for team-building fun!
-
Congratulations to Talus Bio COO, Michelle Briscoe, for being honored by the Puget Sound Business Journal as one of the 2024 Outstanding LGBTQIA+ Voices in Seattle’s business leadership community! Michelle brings a passion for fostering inclusive and welcoming workplaces to Talus Bio every day, and we are very proud to see her leadership in the biotech community acknowledged with the award.
Meet Michelle, OUTbio Seattle co-founder and all-around champion of queer people throughout the Puget Sound region. She’s not just the foundation of OUTbio Seattle – she’s the bedrock. Join us in celebrating Puget Sound Business Journal’s recognition of Michelle Briscoe in its 2024 Outstanding Voices program recognizing the leaders that lift up our LGBTQ+ family in Seattle’s business community and beyond. Michelle brings the same dedication to inclusion to Talus Bio, where she serves as Chief Operating Officer leading a team discovering new transcription factor inhibitors for cancer, inflammation, and other diseases. In her role on Talus Bio’s executive leadership team, Michelle makes it a priority to meet with each new team member personally and help set an example of openness and inclusivity that make Talus Bio a safe, warm, and welcoming workplace. Outside of OUTbio, and beyond business, Michelle enjoys traveling. She’s a particular fan of Türkiye, and has been to Istanbul 11 times. Her favorite part? Seeing that amazing city through the eyes of someone visiting for the first time. At OUTbio Seattle, we find that she brings that same spirit of curiosity and enthusiasm as she guides the organization in building community here in Seattle, too. We hope you’ll take a moment to say hello to Michelle at our events this summer – and give her a well-deserved pat on the back!
-
Talus Bio is getting very excited about the American Society For Mass Spectrometry (ASMS) Annual Conference that starts this weekend, and we'll be very well represented! If you're attending the conference, be sure to check out one (or all) of the great opportunities to learn more about the cutting-edge transcription factor drug discovery powered by AI being done at Talus Bio presented by William Fondrie, Lindsay Pino, Daniele Canzani, PhD, Sebastian Paez, Andrea Gutierrez, and Julia Robbins.
-
+3
-
Talus Bio reposted this
Chief Operating Officer and Chief Financial Officer at Talus Bio | Co-founder & Board Member of OUTbio - Seattle 🏳️🌈 | Board Member of HBA - Seattle Chapter
I'm looking forward to this! Transforming Healthcare and Drug Discovery with Artificial Intelligence (AI) Presenting by HBA Seattle May 20th, 2:00 - 5:30 pm at Adaptive Biotechnologies Corp. Speakers: Shweta Maniar Global Director, Healthcare & Life Sciences at Google Cloud Jeremy Forman, VP, R&D, Data, & Analytics at Pfizer (Seagen) Kate Ostbye, Director, Enterprise Data Science and Machine Learning at Pfizer (Seagen) Registration link: https://bit.ly/3vLZz5x
-
Thousands of molecules screened against thousands of proteins = millions of interactions to find transcription factor inhibitors. 30+ Evosep Biosystems 96-sample tip boxes, which is paired with our Bruker Daltonics timsTOF Ultra for high throughput running at 60 samples a day and 5000 interactions per sample (Daniele Canzani, PhD for scale). What do you think, Shourjo Ghose Ph.D. Daniel Hornburg, PhD ? Of course, we're just getting started for 2024. Another ~36 plates' worth of samples slated to start this upcoming week with our rhabdomyosarcoma screen kickoff. Stay tuned and see you at #ASMS2024! #TeamMassSpec #chemoproteomics #DrugDiscovery #HighThroughputScreens